Chiasma Inc (NASDAQ:CHMA)

4.44
Delayed Data
As of Aug 12
 -0.12 / -2.63%
Today’s Change
2.88
Today|||52-Week Range
7.75
-10.48%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$262.3M

Company Description

Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The firm's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Waltham, MA.

Contact Information

Chiasma, Inc.
140 Kendrick Street
Needham Massachusetts 02494
P:(617) 928-5300
Investor Relations:

Employees

Shareholders

Other institutional29.18%
Individual stakeholders21.70%
Mutual fund holders14.41%

Top Executives

Raj KannanChief Executive Officer & Director
Mark J. FitzpatrickPresident & Chief Financial Officer
William LudlamSenior VP-Clinical Development & Medical Affairs
David PlanteVice President-Information Technology
Anand VaradanChief Commercial Officer & Executive VP